Autopsy report · NCT00350844

Hydroxyurea for Children and Young Adults With Sickle Cell Disease and Pulmonary Hypertension

“Low subject accrual”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 1 year 11 months before it stopped.
• 6 participants enrolled.
• Results were posted on the registry 4 years 11 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 1, Phase 2

Sponsor

Ann & Robert H Lurie Children's Hospital of Chicago

Sponsor type

University, hospital or other

Conditions

Sickle Cell Disease; Pulmonary Hypertension

Interventions

Hydroxyurea

Participants

6

Sites

1

Countries

United States

Trials that died the same way

• Atezolizumab and Bevacizumab in EGFR Mutant NSCLC in Patients With Progressive Disease After Receiving Osimertinib
  “low accrual” (78% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.